Although pandemics are rare, planning and preparation for responding to them plays a crucial role in preventing their spread. The management and control of pandemics such as COVID-19 relies heavily on a country's health capacity. Measuring vulnerability to pandemics in geographical areas could potentially delay a pandemic's exponential growth and reduce the number of cases, which would alleviate the disease impact on communities and the health care sector. The aim of this study is to generate an area-level COVID-19 Pandemic Vulnerability Index (CPVI) and to assess its correlation with COVID-19 cases. Data were collected for Local Government Areas (LGAs) across Australia from different sources including Australia Bureau of Statistics, Australian Institute of Health and Welfare, and General Transit Feed Specification. Based on recent official reports about the COVID-19 outbreak, 18 factors were identified as influencing vulnerability to the disease within LGAs. Using factor analysis, four latent factors were identified and named as sociodemographic, medical conditions, transportation, and land use. Predicted factor scores were summed to generate a CPVI for each LGA. The CPVI was evaluated by correlating with confirmed cases of COVID-19 standardised by adult population in New South Wales and Victoria, the two Australian states with the highest numbers of confirmed cases. There was a statistically significant correlation between the CPVI and COVID-19 in New South Wales (r = 0.49) and Victoria (r = 0.48). LGAs scoring higher on the CPVI also had a higher absolute number of cases. The CPVI could be used by policymakers to identify at-risk areas and to develop preparedness and response plans to help mitigate the spread of COVID-19 and future pandemics.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292828 | PMC |
http://dx.doi.org/10.1016/j.healthplace.2021.102629 | DOI Listing |
BMC Res Notes
January 2025
Department of Cellular and Molecular Biology, School of Biology and Institute of Biological Sciences, Damghan University, Damghan, Iran.
Background And Objective: The coronavirus pandemic, with a wide range of clinical manifestations, is considered a serious emergency in increasing anxiety for vulnerable groups of young people such as students. The purpose of this study is to look into how COVID-19 affects depression and anxiety in students at Damghan University. It also aims to determine how non-pharmaceutical intervention (NPI) education affects COVID-19 anxiety and related aspects.
View Article and Find Full Text PDFBMC Pregnancy Childbirth
January 2025
School of Education, University of Sheffield, Sheffield, UK.
New parenthood in ordinary times can be a vulnerable and unpredictable time. The Covid-19 pandemic brought additional, unprecedented changes to policy and practice that drastically impacted on the experiences of parents. This study aimed to enhance our understanding of the experiences of new parents during the pandemic by qualitatively analysing their experiences.
View Article and Find Full Text PDFJ Gen Intern Med
January 2025
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA.
Background: COVID-19 increased the burden of childcare on parents, leaving women vulnerable to increased disparities in the division of domestic labor. Women healthcare workers may be at heightened risk of worsening gender parity in the workplace as a result.
Objective: To examine the impact of the COVID-19 pandemic on gender parity in the division of household responsibilities among women healthcare workers.
JAMA Netw Open
January 2025
RAND, Boston, Massachusetts.
Importance: Delivery of mental health care through telehealth (telemental health care) increased after the onset of the COVID-19 pandemic. Little is known about the speed of adoption (diffusion) of telemental health in the care in the care of individuals with schizophrenia.
Objectives: To characterize telemental health care diffusion in mental health agencies serving Medicaid beneficiaries with schizophrenia and the beneficiary-level association of telemental health care use with race and ethnicity.
Commun Med (Lond)
January 2025
Nuffield Department of Primary Health Care Sciences, University of Oxford, Oxford, UK.
Background: Sotrovimab is a neutralising monoclonal antibody (nMAB) currently available to treat extremely clinically vulnerable COVID-19 patients in England. Trials have shown it to have mild to moderate side effects, however, evidence regarding its safety in real-world settings remains insufficient.
Methods: Descriptive and multivariable logistic regression analyses were conducted to evaluate uptake, and a self-controlled case series analysis performed to measure the risk of hospital admission (hospitalisation) associated with 49 pre-specified suspected adverse outcomes in the period 2-28 days post-Sotrovimab treatment among eligible patients treated between December 11, 2021 and May 24, 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!